Arc en Demencias 2012

Madrid, 10 y 11 de febrero de 2012

Viernes, 10 de febrero de 2012

16:00-16:15 Bienvenida
  Dr. Rafael Blesa González
  Dr. Pablo Martínez-Lage Álvarez
  Dr. Ramón Estiarte (Director SNC, Analgesia & Respiratorio de Esteve)

16:15-16:45 Rivastigmina Parche en los congresos de 2011
  Dr. Rafael Blesa González
  • Compliance of patients with Alzheimer’s disease to treatment with transdermal rivastigmine and its effectiveness and tolerability in daily practice (AD/PD, poster presentation)
  • Efficacy and safety of acetylcholinesterase inhibitors (ACHIS) and memantine: Results of a recent systematic review and meta-analysis (AD/PD, poster presentation)
  • The long-term cognitive outcomes of Alzheimer’s disease - Influence of APOE genotype, NSAID therapy and cholinesterase inhibitor treatment (AD/PD, poster presentation)

  Dr. Pablo Martínez-Lage Álvarez
  • Effect of combination therapy with memantine and rivastigmine patch on agitation behavior in patients with mild to moderate Alzheimer’s disease: A 24- week prospective, multicenter, randomized, open-label clinical trial (AD/PD, poster presentation)
  • Long-term response to cholinesterase inhibitor treatment in Alzheimer’s disease: an fMRI study (EFNS, SC322)
  • Results of a long-term safety study of rivastigmine capsules and patch in patients with mild to moderate dementia associated with Parkinson’s disease (AD/PD, poster presentation)

16:45-18:15 MESA 1. Aspectos epidemiológicos y patogenéticos de la enfermedad de Alzheimer
  Moderador: Cristóbal Carnero Pardo
  Dr. Juan Fortea Ormaechea
  • Borrelia burgdorferi: Risk factor in Alzheimer’s disease (WCN)
  • Dementia in the developing world (WCN)
  Dr. Alberto Villarejo Galande
  • Subjective memory complaints may predict incident MCI in a population-based cohort (AAN, P03.182)
  • Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: The Mayo Clinic Study of Aging (AAN, IN1-1.008)
  Dra. Raquel Sánchez del Valle Díaz
  • Genetics of late-onset neurodegenerative brain diseases (AD/PD, Plenary Lecture)
  • Soluble Ab oligomers isolated directly from ad cortex are sufficient to induce multiple phenotypic features of Alzheimer’s disease (AD/PD, Sponsored symposia in plenary and parallel)
Dra. Eugenia Marta Moreno

- Prevalence, incidence, progression, reversion and risk factors for Mild Cognitive Impairment in the Sydney Memory and Aging Study (IPA, FC09.01)
- Depression and cognitive decline: Etiologic links in the Singapore Longitudinal Aging Studies (IPA, P04.01)

Dra. María Dolores Martínez Lozano

- Concepts of preclinical dementias (AAIC, S2-02-01)
- Tau-dependent cytotoxicity and prion-like properties of amyloid-beta oligomers seeded by pyroglutamate modified amyloid-beta (AAIC, F5-02-01)

18:15-18:30 Café

18:30-20:00 MESA 2. Enfermedad de Alzheimer y deterioro cognitivo ligero: marcadores diagnósticos

Moderador: Alberto Lleó Bisa

Dr. Juan Fortea Ormaechea

- Resting state network abnormalities in Alzheimer’s disease: Beyond the default mode network (EFNS, SC210)
- Clinicopathologic Study of Alzheimer’s disease: Alzheimer mimics (WCN)

Dr. Alberto Villarejo Galende

- Alzheimer-Signature MRI biomarker predicts AD dementia in cognitively normal adults (AAN, SC01.005)
- The Fornix sign: A potential diagnostic sign for Alzheimer’s disease based on diffusion tensor imaging (AAN, S04.003)

Dra. Raquel Sánchez del Valle Díaz

- Biomarkers for predicting and monitoring progression of Alzheimer’s disease: The Alzheimer’s disease neuroimaging initiative (AD/PD, Symposium in Parallel)
- Prognostic value of CSF biomarkers for Alzheimer’s disease in subjects with mild cognitive impairment: A clinical follow-up study over 9.2 years (AD/PD, Symposium in Parallel)

Dra. Eugenia Marta Moreno

- An Alzheimer’s Disease International Alzheimer’s Netherlands Symposium. Assessment and outcome of older subjects with Subjective Cognitive Impairment (SCI) and No Cognitive Impairment (NCI): Findings from a 7-year longitudinal study and implications for future clinical trials (IPA, S20.01)
- A European Alzheimer’s disease consortium symposium prediction of Alzheimer-type dementia in subjects with mild cognitive impairment: The DESCRIPA Study (IPA, S25.02)

Dra. María Dolores Martínez Lozano

- Ordering of Alzheimer’s disease biomarkers (AAIC, IC-02-04)
- CSF biomarker and pib-pet–derived betaamyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects (AAIC, IC-02-03)

21:30 Cena
Sábado, 11 de febrero de 2012

9:00-10:30 MESA 3. Perspectivas terapéuticas en la enfermedad de Alzheimer. Nuevos fármacos y mecanismos de acción
Moderador: Guillermo García Ribas

Dr. Juan Fortea Ormaechea
- Prolonged visual memory enhancement after direct current stimulation in Alzheimer’s disease (WCN, oral comunicacion)
- Long-term response to cholinesterase inhibitor treatment in Alzheimer’s disease: AN fMRI Study (EFNS, SC322)

Dr. Alberto Villarejo Galende
- Improvement of cognitive functions in Alzheimer’s patients following treatment with repetitive transcranial magnetic stimulation interlaced with cognitive training (randomized clinical study): Interim results (AAN, IN1-1.011)
- Clinical trial results of the first controlled clinical trial of zinc-based therapy for Alzheimer’s disease and mild cognitive impairment (AAN, P07.220)

Dra. Raquel Sánchez del Valle Díaz
- Vasogenic edema in anti-amyloid therapeutic trials - Towards understanding the pathophysiological mechanisms (AD/PD, Sponsored Symposia in plenary and parallel)
- Prevention vs. intervention, or one drug good, two drugs better: Combination therapy improves amyloid clearance in transgenic mice (AD/PD, Sponsored Symposia in plenary and parallel)

Dra. Eugenia Marta Moreno
- Future of clinical trials (IPA, P02.01)
- Involvement of puromycin-sensitive aminopeptidase in metabolism of tau protein in cultured cells (IPA, PS02.11)

Dra. María Dolores Martínez Lozano
- Imaging and cerebrospinal fluid biomarker results of a phase II dose-ranging study of ELND005 (SCYLLO-INOSITOL) in mild-to-moderate Alzheimer’s disease (AAIC,04-06-07)
- CNTF peptidergic drugs: a pharmacological approach to enhance neurogenesis, neuronal plasticity and cognition (AAIC, S3-02-05)

10:30-11:00 Pausa-café

11:00-12:30 MESA 4. Demencia de la enfermedad de Parkinson y demencia con cuerpos de Lewy
Moderador: Dr. Juan Carlos Martínez Castrillo

Dr. Juan Fortea Ormaechea
- Association of CSF T and β-amyloid markers with neuropsychological, morphometric and clinical outcomes in Parkinson’s disease: A longitudinal study (MDS, 437)
- Prefrontal dopaminergic receptor abnormalities and cognitive functions in Parkinson’s disease (MDS, 452)

Dra. Eugenia Marta Moreno
- CSF biomarkers differentiate dementia with Lewy bodies from Alzheimer’s disease (MDS, 964)
- Cell adhesion molecules in Lewy bodies dementia (MDS, 966)
Dra. María Dolores Martínez Lozano
- Efficacy of atypical neuroleptics and acetylcholinesterase inhibitors in treating neuropsychiatric symptoms in Parkinson’s disease (MDS, 487)
- The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: A randomized, double-blind, placebo-controlled, multi-center study (MDS, 834)

Dr. John C. Morris, MD
Friedman Distinguished Professor of Neurology
Director, Knight Alzheimer Disease Research Center
Director, Harvey A. Friedman Center for Aging
Washington University School of Medicine, Sant Louis, Missouri, USA

13:15-13:30 Conclusiones y cierre
Dr. Rafael Blesa González
Dr. Pablo Martínez-Lage Álvarez
Dr. Javier Arranz (Departamento Médico Área SNC de Esteve)

14:00 Comida

Actividad acreditada por el Comité de Docencia y Acreditación de la SEN

Actividad acreditada por el Consell Català de Formació Continuada de les Professions Sanitàries y por la Comisión de Formación Continuada del Sistema Nacional de Salud